The global available market for bone regeneration products is estimated at US$ 18 billion per annum, including US market reaching up to US$ 2 billion per annum.
The prevalence of bone fractures is projected to increase due to the aging population and rising incidences of sports injuries and accidents.
The bone regeneration industry is a rapidly growing sector, with a significant demand for effective and affordable methods for healing bone defects. As the population ages, the incidence of conditions such as osteoporosis and osteoarthritis is also increasing, further driving demand for bone regeneration products.
Besides, while being relatively inexpensive to produce and having a long shelf life, the INROST compound is proven to be non-toxic, and not to accumulate in the body.
Initial preclinical trials and some additional studies have been completed in Russia, the effectiveness of the drug has been confirmed.
Additional studies have shown that the drug is not toxic, does not accumulate in the body, does not disrupt the natural physiological stages of healing and is genetically safe.
Patents have been obtained in the USA, Canada, China, United Kingdom, France, Germany, Japan and Russia.
